Initiative for Vaccine Research, Department of Immunization, Vaccines & Biologicals, World Health Organization, Avenue Appia 20, 1211-CH 27, Geneva, Switzerland.
Malar J. 2012 Jan 9;11:11. doi: 10.1186/1475-2875-11-11.
Development and Phase 3 testing of the most advanced malaria vaccine, RTS,S/AS01, indicates that malaria vaccine R&D is moving into a new phase. Field trials of several research malaria vaccines have also confirmed that it is possible to impact the host-parasite relationship through vaccine-induced immune responses to multiple antigenic targets using different platforms. Other approaches have been appropriately tested but turned out to be disappointing after clinical evaluation. As the malaria community considers the potential role of a first-generation malaria vaccine in malaria control efforts, it is an apposite time to carefully document terminated and ongoing malaria vaccine research projects so that lessons learned can be applied to increase the chances of success for second-generation malaria vaccines over the next 10 years. The most comprehensive resource of malaria vaccine projects is a spreadsheet compiled by WHO thanks to the input from funding agencies, sponsors and investigators worldwide. This spreadsheet, available from WHO's website, is known as "the rainbow table". By summarizing the published and some unpublished information available for each project on the rainbow table, the most comprehensive review of malaria vaccine projects to be published in the last several years is provided below.
最先进的疟疾疫苗 RTS,S/AS01 的研发和 3 期测试表明，疟疾疫苗研发正在进入一个新阶段。几种研究性疟疾疫苗的现场试验也证实，通过针对多种抗原靶点的疫苗诱导免疫反应，可以影响宿主-寄生虫关系，使用不同的平台。其他方法也经过了适当的测试，但在临床评估后结果令人失望。随着疟疾界考虑第一代疟疾疫苗在疟疾控制工作中的潜在作用，现在正是仔细记录已终止和正在进行的疟疾疫苗研究项目的适当时机，以便将经验教训应用于增加未来 10 年内第二代疟疾疫苗成功的机会。疟疾疫苗项目最全面的资源是世卫组织编制的电子表格，这要归功于来自世界各地的供资机构、赞助商和研究人员的投入。该电子表格可在世卫组织的网站上获得，被称为“彩虹表”。通过总结彩虹表上每个项目的已发表和一些未发表的信息，下面提供了过去几年中发表的关于疟疾疫苗项目的最全面综述。
